Skip to main content
OpenTrials
Completed

NCT Number: NCT03934710

Mood Effects of Serotonin Agonists Extended

In this study we are examining the effects of repeated very low doses of serotonin agonists on mood individuals with negative mood.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Matthew Bona

Chicago, Illinois, 60637, United States

About this study

Here, we are examining the effects of four repeated low doses of lysergic acid diethylamide (LSD), compared to placebo, administered to healthy adults at 3-4 day intervals, on mood, cognitive performance and responses to emotional tasks

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English fluency
  • High school level education
  • BMI between 19 and 30

Exclusion criteria

  • Diagnosed medical condition
  • women who are nursing, pregnant, or plan to become pregnant within 3 months
  • History of psychotic disorder or family history of psychotic disorder

Treatment and study plan

Placebo

Drug

Drug will be administered in solution form

Serotonin agonist - 13ug

Drug

13ug lysergic acid diethylamide

Other names: LSD

Serotonin agonist - 26ug

Drug

26ug lysergic acid diethylamide

Other names: LSD

Primary outcomes

  1. DASS-21

    Time frame: End of session 5, approximately 2 weeks from baseline

    The primary outcome measure is the depression anxiety and stress scale (DASS) 21. This self-report measure contains 21 items and the range of scores for depression is 0-42, anxiety 0-42, and stress 0-42. Our primary outcome measure is total depression scale ratings during session 5, with lower scores indicating lower ratings of depression.

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Acronym: MESA-E

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
May 2, 2019
Registry last updated
Nov 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.